Therapeutic Potential of EP3 Receptor Antagonists for Treatment of Noninsulin Dependent Diabetes Mellitus across Multiple Preclinical Models
Matthew M. Rankin(Janssen (United States)), Lisa Norquay(Springhouse), Brian Rady(Springhouse), Volha Tryputsen(Springhouse), Shefali Patel(Johnson & Johnson (United States)), Lili Guo(Henan University of Science and Technology), Paul L. Stahle(National Institutes of Health), George Ho(Springhouse), Ivona Bakaj(Springhouse), Mariusz Lubomirski(Springhouse), Xuqing Zhang(Army Medical University), Mark J. Macielag(Springhouse), Avijit Ghosh(Springhouse), Bin Zhu(Springhouse), Yifan Shi(Johnson & Johnson (United States)), Shuyuan Zhao(Johnson & Johnson (United States)), Michael P. Winters(Springhouse)
Cited by 2
Related Papers
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase
|Nature Medicine|2005|1k
Growth and Regeneration of Adult β Cells Does Not Involve Specialized Progenitors
|Developmental Cell|2007|551
Very Slow Turnover of β-Cells in Aged Adult Mice
|Diabetes|2005|465
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
|Journal of Medicinal Chemistry|2005|430
Adaptive β-Cell Proliferation Is Severely Restricted With Advanced Age
|Diabetes|2009|322